5-Amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine

Alimentary Pharmacology and Therapeutics

Volumn 10, Issue 6, 1996, Pages 941-947

  Stretch, G L ^b   Campbell, B J ^a   Dwarakanath, A D ^a   Yaqoob, M ^c   Stevenson, A ^c   Morris, A I ^c   Rhodes, J M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; MESALAZINE; OLSALAZINE; SULFALAZINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG FORMULATION; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; ULCERATIVE COLITIS;

EID: 0029830881     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1996.85257000.x     Document Type: Article

References (24)

1. Mehta RP. Acute interstitial nephritis due to 5-ASA. Can Med Assoc J 1990; 143: 1031-2.
2. Masson EA, Rhodes JM. Mesalazine associated nephrogenic diabetes insipidus presenting as weight loss. Gut 1992; 33: 563-4.
3. Committee on Safety of Medicines, Nephrotoxicity associated with Asacol. Curr Probl Pharmacovigilance 1990; 30: 2.
4. Dwarakanath AD, Michael J, Allan RN, Sulphasalazine induced renal failure. Gut 1992; 33: 1006-7.
5. Norlander B, Gotthard R, Strom M. Pharmacokinetics of a 5-ASA enteric coated tablet in patients with Crohn's disease or ulcerative colitis and in healthy volunteers. Aliment Pharmacol Ther 1990; 4: 497-505.
6. Norlander B, Gotthard R, Strom M. Steady state pharmacokinetics of enteric coated 5-ASA tablets in healthy volunteers and in patients with Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 1991; 5: 291-300.
7. Laursen LS, Stokholm M, Bukhave K, Rask-Madsen J, Lauritsen K. Disposition of 5-ASA by olsalazine and three mesalazine preparations with ulcerative colitis: A comparison of intraluminal colonic concentrations, serum values and urinary excretion. Gut 1990; 31: 1271-6.
8. Ewe K, Becker K, Ueberschaer B. Absorption of 5-ASA from a mesalazine and an olsalazine preparation in ulcerative colitis in remission. Gastroenterology 1994; 106(4), A678.
9. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 1955; 2: 1041-8.
10. Dew MJ, Ebden P, Kidwai NS, et al. Comparison of the absorption and metabolism of Sulphasalazine and acrylic-coated 5ASA in normal subjects and patients with colitis. Br J Clin Pharmacol 1984; 17: 474-6.
11. Yaqoob M, Bell GM, Stevenson A, Mason H, Percy DF. Renal impairment with chronic hydrocarbon exposure. Q J Med 1993; 86: 165-74.
12. Myers B, Evans DNW, Rhodes J, et al. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut 1987; 28: 196-200.
13. Rao SSC, Read NW, Brown C, Bruce C, Holdsworth CD. Studies on the mechanism of bowel disturbance in ulcerative colitis. Gastroenterology 1987; 93: 934-40.
14. Ireland A, Priddle JD, Jewell DP. Acetylation of 5-ASA by isolated human epithelial cells. Clin Sci 1990; 78: 105-11.
15. Pieniaszek HJ, Bates TR. Capacity-limited gut wall metabolism of 5-aminosalicylic acid, a therapeutically active metabolite of sulphasalazine, in rats. J Pharmacol Sci 1979; 68: 1323-5.
16. Allgayer H, Ahnfelt NO, Frank K, et al. Acetylation phenotype independent colonic N-acerylation of 5-aminosalicylic acid : an example for intestinal drug metabolism. Gastroenterology 1985; 88: 1303.
17. Hearse DJ, Weber WW. Multiple N-acetyltransferases and drug metabolism. Tissue distribution, characterisation and significance of mammalian N-acetyltransferase. Biochem J 1973; 132: 519-26.
18. Evans DAP. Acetylation polymorphisms. Proc R Soc Med 1964; 57: 508-11.
19. Calder IC, Funder CC, Green CR, Ham KN, Tange JD. Nephrotoxic lesions from 5ASA. Br Med J 1972; 1: 152-4.
20. Calder IC, Funder CC, Green CR, Ham KN, Tange JD. Comparative nephrotoxicity of aspirin and phenacetin derivatives. Br Med J 1971; 4: 518-21.
21. Riley SA, Lloyd DR, Mani V. Tests of renal function in patients with quiescent colitis: effects of drug treatment. Gut 1992; 33: 1348-52.
22. Riley SA, Mani V, Goodman MJ, et al. Comparison of delayed release 5-ASA (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 1988; 29: 669-74.
23. Mahmud N, Stinson J, O'Connell M, et al. Microalbuminuria: A disease activity marker for inflammatory bowel disease. Gastroenterology 1993; 104(4): A736.
24. Lundberg C, Åsberg I, Carlin G, Berglindh T. 5-Aminosalicylic acid (5-ASA) induced nephrotoxicity in dose-dependent in rats. Gut 1996; 38: A635.